RayKnowChina Research Map
Shortlist

Cancer

Lung cancer in Changchun

长春 肺癌

All diseases in Changchun

4 hospitals in Changchun

Order: papers led on lung cancer, 2021–2025, then A–Z. Research activity, not a rating of care.

Only hospitals listed for lung cancer: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Changchun may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.

  1. 112 papers led
  2. 39 papers led
    No open trial led
  3. 37 papers led
    No open trial led
  4. 31 papers led
    No open trial led

Lung cancer in every city Changchun on the disease page, with the national map

46

open trials on lung cancer with a hospital in Changchun

Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Changchun as lead sponsor or study site. 1 of them are led by a hospital in Changchun. Check the registry for the current status. Whether someone can take part is decided by the study team.

Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.

  1. Recruiting
    Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
    Phase
    Phase 3
    Started
    2026-01
    Posted
    Registry
    NCT07195695

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Shijiazhuang, Suzhou, Taizhou, Tianjin, Wuhan, Xuzhou, Yangzhou, Zhengzhou

  2. Recruiting
    Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2026-01
    Posted
    Registry
    NCT07222566

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jiangmen, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Wenzhou, Wuhan, Xiangyang, Xinxiang, Yangzhou, Zhengzhou

  3. Recruiting
    RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
    Phase
    Phase 3
    Started
    2026-04
    Posted
    Registry
    NCT07416474

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 66 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jiangmen, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Urumqi, Wenzhou, Wuhan, Xiamen, Xiangyang, Xinxiang, Xuzhou, Yantai, Yinchuan, Zhengzhou, Zhuhai

  4. Recruiting
    A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
    Phase
    Phase 3
    Started
    2026-10
    Posted
    Registry
    NCT07541170

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Changchun, Chengdu, Foshan, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Shenzhen, Suzhou, Taizhou, Tianjin

  5. Recruiting
    A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07622186

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Jinan, Kunming, Nanchang, Nanjing, Nanning, Shenyang, Taiyuan, Tianjin, Xi'an, Xiamen, Xiangyang, Zhengzhou

  6. Recruiting
    A Study of DS-3939a in Participants With Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07739966

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changchun, Changsha, Guangzhou, Hangzhou, Harbin, Jinan, Shanghai, Taizhou, Tianjin, Wuhan, Zhengzhou

  7. Recruiting
    Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
    Phase
    Phase 2/Phase 3
    Started
    2025-01
    Posted
    Registry
    NCT06712316

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chongqing, Hangzhou, Jinan, Shanghai, Shantou, Shijiazhuang, Suzhou, Taizhou, Wuhan, Yangzhou

  8. Recruiting
    Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-02
    Posted
    Registry
    NCT06712355

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Shanghai, Shantou, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Wenzhou, Wuhan, Xiangyang, Xinxiang, Yangzhou, Zhengzhou

  9. Recruiting
    Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-04
    Posted
    Registry
    NCT06801834

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Linyi, Nanchang, Nanjing, Shanghai, Shenzhen, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xinxiang, Yangzhou, Zhengzhou

  10. Recruiting
    A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
    Phase
    Phase 1
    Started
    2025-02
    Posted
    Registry
    NCT06839105

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesChangchun, Changsha, Fuzhou, Guangzhou, Hangzhou, Harbin, Kunming, Luoyang, Nanchang, Shanghai, Shenyang, Wuhan

  11. Recruiting
    A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
    Phase
    Phase 3
    Started
    2025-04
    Posted
    Registry
    NCT06875310

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou

  12. Recruiting
    A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
    Phase
    Phase 1/Phase 2
    Started
    2025-05
    Posted
    Registry
    NCT06892548

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Xi'an, Xiamen, Xiangyang, Xinxiang, Xuzhou, Yichang, Zhengzhou

  13. Recruiting
    Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-10
    Posted
    Registry
    NCT06899126

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xiangyang, Zhengzhou

  14. Recruiting
    Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-05
    Posted
    Registry
    NCT06902350

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Changchun

  15. Recruiting
    A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
    Phase
    Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT06962865

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Jinan, Kunming, Linyi, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiangyang, Yantai, Zhengzhou

  16. Recruiting
    A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT07010263

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Harbin, Jiangmen, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Xinxiang, Yinchuan, Zhengzhou, Zunyi

  17. Recruiting
    A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
    Phase
    Phase 1/Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07111520

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesChangchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan, Nanchang, Qingdao, Shanghai, Shijiazhuang, Suzhou, Tianjin, Wuhan, Xiangyang, Xinxiang, Xuzhou, Yangzhou

  18. Recruiting
    A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
    Phase
    Not given
    Started
    2025-12
    Posted
    Registry
    NCT07143045

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesChangchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Harbin, Hefei, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shenyang, Shenzhen, Taiyuan, Tianjin, Wuhan, Xiamen, Yangzhou, Zhengzhou

  19. Recruiting
    A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07182682

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 47 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xuzhou, Zhengzhou

  20. Recruiting
    A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
    Phase
    Phase 3
    Started
    2025-11
    Posted
    Registry
    NCT07218146

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Taizhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  21. Recruiting
    D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
    Phase
    Phase 3
    Started
    2024-03
    Posted
    Registry
    NCT06300177

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 63 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi

  22. Recruiting
    A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
    Phase
    Phase 3
    Started
    2024-04
    Posted
    Registry
    NCT06312137

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Suzhou, Taizhou, Wuhan, Xi'an, Zhengzhou

  23. Recruiting
    Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
    Phase
    Phase 3
    Started
    2024-06
    Posted
    Registry
    NCT06422143

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Nanchang, Shanghai, Taizhou, Urumqi, Wenzhou, Wuhan, Xiamen, Yangzhou, Zhengzhou

  24. Recruiting
    A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
    Phase
    Phase 3
    Started
    2024-08
    Posted
    Registry
    NCT06452277

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanjing, Shanghai, Taizhou, Wuhan, Xiamen

  25. Recruiting
    Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
    Phase
    Phase 3
    Started
    2024-09
    Posted
    Registry
    NCT06496048

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangchun

  26. Recruiting
    A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06496490

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Foshan, Fuzhou, Guangzhou, Harbin, Jiangmen, Nanchang, Nanning, Shanghai, Tianjin, Xi'an, Zhengzhou, Zunyi

  27. Recruiting
    Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
    Phase
    Phase 1
    Started
    2024-10
    Posted
    Registry
    NCT06598306

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangchun, Shanghai

  28. Recruiting
    A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06668103

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChangchun, Harbin, Shanghai, Wuhan

  29. Recruiting
    Study of Risk Factors and Prediction of Blood Clots After Lung Cancer Surgery
    Phase
    Not given
    Started
    2024-11
    Posted
    Registry
    NCT07439991

    Age 18 years to Not stated (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  30. Recruiting
    A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
    Phase
    Phase 3
    Started
    2023-11
    Posted
    Registry
    NCT05920356

    Age 18 years to 100 years (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Weifang, Wuhan, Xi'an, Xiamen, Xiangyang, Zhengzhou

  31. Recruiting
    A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2023-11
    Posted
    Registry
    NCT05924841

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangchun

  32. Recruiting
    Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
    Phase
    Phase 3
    Started
    2023-11
    Posted
    Registry
    NCT06095583

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Qingdao, Shanghai, Shenyang, Shenzhen, Taiyuan, Taizhou, Tianjin, Wuhan, Xiamen, Yinchuan, Zhengzhou

  33. Recruiting
    A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
    Phase
    Phase 3
    Started
    2022-03
    Posted
    Registry
    NCT04928846

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Zhanjiang, Zhengzhou

  34. Recruiting
    Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2022-09
    Posted
    Registry
    NCT05168566

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Linyi, Nanjing, Shanghai, Shenyang, Wuhan, Zhengzhou

  35. Recruiting
    Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
    Phase
    Phase 2
    Started
    2022-05
    Posted
    Registry
    NCT05334277

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesChangchun, Chengdu, Foshan, Guangzhou, Hangzhou, Jiangmen, Nanchang, Shenyang, Urumqi, Wuhan, Xi'an, Xuzhou, Zhengzhou

  36. Recruiting
    JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2022-12
    Posted
    Registry
    NCT05490472

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Changchun, Jinan

  37. Recruiting
    Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
    Phase
    Phase 1/Phase 2
    Started
    2022-12
    Posted
    Registry
    NCT05579366

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan

  38. Recruiting
    Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
    Phase
    Phase 1
    Started
    2021-07
    Posted
    Registry
    NCT04886804

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Nanning, Shanghai, Wuhan, Xiamen, Zhengzhou

  39. Recruiting
    Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-09
    Posted
    Registry
    NCT04930432

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 56 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Weifang, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou

  40. Recruiting
    Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-11
    Posted
    Registry
    NCT05024214

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Bengbu, Changchun, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Kunming, Shanghai, Shenyang, Taiyuan, Tianjin, Zhengzhou, Zhuhai

  41. Recruiting
    Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
    Phase
    Phase 2/Phase 3
    Started
    2020-12
    Posted
    Registry
    NCT04613596

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 30 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanning, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Taizhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  42. Recruiting
    Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
    Phase
    Phase 1/Phase 2
    Started
    2019-07
    Posted
    Registry
    NCT04270591

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Zhengzhou

  43. Recruiting
    A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer
    Phase
    Phase 1
    Started
    2008-01
    Posted
    Registry
    NCT02889666

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangchun, Shanghai

  44. Not yet recruiting
    A Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-center, Observational Study
    Phase
    Not given
    Started
    2026-02
    Posted
    Registry
    NCT07375979

    Age 40 years to 74 years (registered criteria)

    Led by Shanghai Pulmonary Hospital; 5 listed hospitals as study sitesChangchun, Kunming, Shanghai, Shenyang, Zhengzhou

  45. Not yet recruiting
    Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT06885840

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Foshan, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Shenyang, Tianjin, Wuhan, Xi'an, Zhengzhou

  46. Not yet recruiting
    A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2023-11
    Posted
    Registry
    NCT05990127

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Luoyang, Nanchang, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xinxiang, Xuzhou, Yinchuan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

Disease research in Changchun

Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.

A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.

Papers led and open trials led by hospitals in Changchun, by disease
CancerBlood disordersOther diseases
HospitalNasopharyngeal carcinomaOesophageal squamous cell carcinomaHepatocellular carcinomaStomach cancerLung cancerPancreatic cancerBreast cancerGliomaHepatoblastomaRetinoblastomaChordomaOsteosarcomaGastrointestinal stromal tumourNeuroblastomaEwing sarcomaMultiple myelomaB-cell acute lymphoblastic leukaemiaAplastic anaemiaHaemophagocytic lymphohistiocytosisLymphomaBeta thalassaemiaHaemophilia AAtypical haemolytic uraemic syndromeThrombotic thrombocytopenic purpuraFanconi anaemiaNeuromyelitis optica spectrum disorderIgG4-related diseaseMyasthenia gravisMoyamoya diseaseWilson diseaseBiliary atresiaCoronary heart diseaseCongenital heart diseaseScoliosisAnti-NMDA receptor encephalitisTakayasu arteritisHepatic echinococcosisIdiopathic pulmonary fibrosisLymphangioleiomyomatosisAmyotrophic lateral sclerosisSpinal muscular atrophyFabry diseasePompe diseaseDuchenne muscular dystrophyBehçet diseaseAlport syndromeIgA nephropathyGaucher diseaseNiemann–Pick disease type COsteogenesis imperfectaPrimary biliary cholangitisPrimary sclerosing cholangitisCongenital diaphragmatic herniaHirschsprung diseaseInherited epidermolysis bullosaHereditary angioedemaFamilial adenomatous polyposisLeber hereditary optic neuropathyMajeed syndromeNGLY1 deficiencyISG15 deficiencyShortlist
Affiliated Hospital of Changchun University of Chinese Medicine长春中医药大学附属医院nonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenone6nonenonenone6nonenonenonenonenone3nonenonenonenonenonenonenonenone1nonenonenone1nonenonenonenonenonenonenonenonenonenone
China-Japan Union Hospital, Jilin University吉林大学白求恩第三医院(中日联谊医院)0none212231145122none00131104nonenonenone10nonenonenonenonenone3none22nonenone1542none0none1none10nonenonenone0none0nonenonenone11nonenonenonenonenonenonenonenonenone
First Hospital of Jilin University吉林大学第一医院35761 open417 open1121 open27772 open561 open13017072174 open024243 opennone021none11none142none202 open9252none1none201none03071 open1none0111nonenonenonenone0nonenonenonenone
Jilin Cancer Hospital吉林省肿瘤医院none04039none21nonenonenonenone0nonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Jilin Heart Hospitalnonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Jilin Province FAW General Hospital吉林省一汽总医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Jilin Province People's Hospital吉林省人民医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0none0nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Second Hospital of Jilin University吉林大学第二医院0115173782010none1none111104nonenonenone6nonenonenonenonenonenone5nonenonenonenone123 open21none0none7none2nonenone1none107nonenonenone2nonenonenonenonenonenonenonenonenonenone

Column labels are short names. Choose one to open that disease in Changchun.

Other cities nearby

Straight-line distance from the city centre; counts are hospitals listed for lung cancer.

Counts are listed hospitals only, not every hospital in each city.

Where these numbers come from

Papers

English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions

Trials

ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Changchun on ClinicalTrials.gov

Locations

Locations are shown at city centres. Check the hospital’s website for its address.

Suggest a correctionDownload the data